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ABSTRACT 
Objectives: The objectives of this study were: 1) To compare the prevalence of 
cardiovascular disease and cardiovascular risk factors among different phenotypes of 
Spondyloarthritis (SpA); 2) To assess the differences in cardiovascular disease and 
cardiovascular risk factors between two geographical areas, i.e. Northern Europe vs. 
Mediterranean region; 3) To identify potential predictive factors for high Framingham 
Risk Score regarding disease features in SpA and geographical area.  
Methods: Ancillary analysis of the international, multicentric, observational, cross-
sectional ASAS-COMOSPA study. Cardiovascular disease and cardiovascular risk 
factors were compared depending on SpA phenotype and geographical regions. 
Potential factors associated with higher cardiovascular risk (i.e. Framingham Risk 
Score) were determined by a multiple logistic regression. 
Results: The most frequent cardiovascular risk factor and cardiovascular disease were 
smoking (31.2%) and ischemic heart disease (3.2%), respectively. Regarding SpA 
phenotype, axial SpA patients showed significantly lower prevalence (p<0.05) of 
hypertension (19.2% vs. 33.8% vs. 26.6% for axial, peripheral and mixed phenotypes, 
respectively), type 2 diabetes mellitus (4.3% vs. 8.5% vs. 7.4%), dyslipidemia (13.9% 
vs. 28.4% vs. 15.2%) and ischemic heart disease (2.4% vs. 7.0% vs. 3.2%). Regarding 
geographical area, a higher frequency of hypertension (34.7% vs. 19.4%,), dyslipidemia 
(19.3% vs. 14.4%), obesity (29.3% vs. 20.7%) and ischemic heart disease (6.2% vs. 
1.8%) was observed for Northern Europe vs. Mediterranean Region, respectively.  
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Conclusions: Our results suggest that SpA phenotype and geographical area are 
associated with the prevalence of cardiovascular risk factors and the cardiovascular risk 
itself, observed in patients in the ASAS-COMOSPA cohort.  
 
KEYWORDS: Spondyloarthritis/ Cardiovascular disease/ Cardiovascular risk factors/ 
Socio-demographic characteristics. 
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1. Introduction 
Spondyloarthritis (SpA) is a chronic inflammatory disease that presents under different 
phenotypes depending on the presence of axial or peripheral manifestations [1]. Patients 
with SpA can present predominantly with axial symptoms (axial SpA) [2], with 
peripheral arthritis (peripheral SpA) [3] or both (hereafter called mixed SpA). In 
addition to articular symptoms, many SpA patients exhibit an array of extra-articular 
manifestations including psoriasis, anterior uveitis and inflammatory bowel disease 
(IBD) [4]. This phenotypic presentation generated the division into several subtypes, 
such as ankylosing spondylitis (AS), psoriatic arthritis (PsA), IBD-associated SpA, 
reactive arthritis and undifferentiated SpA [5].  
It has also been reported that patients with SpA present more frequently with 
comorbidities such as cardiovascular (CV) manifestations, among others [6]. These 
comorbidities are of particular interest due to their role and their possible involvement 
in the treatment and prognosis of SpA. An increased mortality has been described in 
SpA patients compared to the general population, together with a greater risk for CV 
mortality [7]. Some studies have shown that SpA patients present also an increased risk 
of cardiovascular disease (CVD) [8,9] compared to the general population. There are 
several factors that may explain this greater risk, e.g. related to chronic systemic 
inflammation, to a higher prevalence of classical CV risk factors [10], and to the 
different treatment modalities depending on the SpA phenotype (i.e. more frequently 
NSAIDs in axial disease). 
There are other factors that could contribute to this high CV risk. Several studies have 
shown that metabolic syndrome and CVD are common in patients with AS and PsA [11-
14]. Nevertheless, the comparison among different SpA phenotypes regarding the 
prevalence of CV risk has not been reported yet. In addition, several factors such as 
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environmental, socio-demographic and behavioural (i.e. smoking, age, socioeconomic 
status, psychological stress, alcohol or unhealthy diet) may also be key CV risk factors 
in SpA patients. This constellation of factors may be involved in the impairment of the 
classical CV risk factors, as well as directly in the CV process. More, it has been noted 
that these factors are associated with increased CV risk [15] in healthy population, with 
frequencies depending on each country and geographical area [18-20]. In fact, recent 
epidemiological studies in general population [19,20] show that CVD and mortality 
rates are higher in Northern European Countries (eg. UK and Germany) than in some 
Mediterranean Countries (eg. Spain and Italy). However, these geographical differences 
have not been studied in SpA patients. Recent data from the ASAS-COMOSPA study 
[21] illustrate that the worldwide distribution of CVD is strikingly more frequent in 
Northern Europe and in USA compared to the rest of the population included in the 
study. 
The ASAS-COMOSPA is an observational, cross-sectional, multicentre and 
international study, with 22 participating countries from 4 continents (Africa, America, 
Asia and Europe), and it was performed under the umbrella of ASAS (Assessment in 
SpondyloArthritis international Society). The ASAS-COMOSPA study had as objectives 
to evaluate the prevalence of comorbidities and their risk factors in SpA patients and to 
evaluate the gap between the available recommendations and their implementation in 
daily practice. 
Thus, our aims in the present study were: 
- First, to compare CVD and CV risk factors among different SpA phenotypes.  
- Secondly, to analyze the differences in SpA characteristics and in CVD/ CV risk 
factors between two geographical areas (Northern European vs. Mediterranean 
region). 
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- Finally, to identify potential factors associated with high Framingham Risk Score 
(FRS) regarding disease features in SpA and geographical area. 
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2. Methods 
2.1. Study design 
This was an ancillary analysis of the ASAS-COMOSPA study, an international, 
observational, cross-sectional and multicentre study [21]. For the present analysis, only 
10 participating countries from two European regions were included: Northern Europe 
(United Kingdom, Germany, Belgium and Netherlands) and Mediterranean area (Spain, 
France, Italy, Morocco, Turkey and Egypt). These countries were selected because of 
dietary similarities (patients from Mediterranean countries consuming the traditional 
Mediterranean diet, which includes high intake of vegetables, legumes, fruits, nuts and 
olive oil), genetic, lifestyle and environmental (e.g. hours of sunlight) [22].  
 
2.2. Participants and recruitment 
Of the 3984 consecutive adult patients belonging to the paternal study [e.g. at least 18 
years old, fulfilling the ASAS criteria (either axial or peripheral) [2,3] and who were 
able to understand and complete questionnaires included in the original study], we 
included all participants from the above specified countries selected for the analysis (a 
total of 2020) [21]; 19 patients were excluded by missing socio-demographic data, 
resulting in 2001 patients included in this present analysis (1353 participants were from 
countries of Mediterranean area and 648 from Northern Europe) (Fig. 1). The study was 
conducted according to guidelines for good clinical practice at the local level. All 
participants gave written informed consent and underwent a comprehensive medical 
history, physical examination, and laboratory tests before enrolment. The working 
protocol was approved by the local ethic committee at each of the intervention centers 
according to the Helsinki Declaration. 
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2.3. Data collection 
A case report form was used to collect the following data: 
A). Demographic and disease characteristics: Demographic characteristics: country of 
origin, age, gender, body mass index (BMI; calculated as weight in kilograms divided 
E\WKHVTXDUHRIKHLJKWLQPHWHUV2EHVHVXEMHFWVZHUHGHILQHGDVSDWLHQWVZLWK%0,
kg/m2) and smoking status as: a) non-smoker [never or past (>3 years)], b) smoker 
[present or past (d 3 years)]. Disease characteristics: disease duration, presence or 
absence of HLA-B27 antigen, SpA phenotype (defined as only axial/ axial and 
peripheral (mixed)/ and only peripheral involvement [3,5]), enthesitis, dactylitis, uveitis, 
psoriasis, and IBD. Current disease activity was measured by CRP (mg/dL) and ESR 
(mm/1h) levels, patient and physician global visual analogue scale (VAS; range from 0 
to 10), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) [23], 
Ankylosing Spondylitis Disease Activity Score (ASDAS; calculated with the CRP) 
[24], and the number of swollen and tender joints (44 joint count). 
B). CVD and CV risk factors: CVD: history of ischaemic heart disease (IHD) or stroke; 
risk factors for CVD: hypertension [defined as history of hypertension or 
antihypertensive therapy or blood pressure (BP) > 140/90 mm Hg (>130/80 mm Hg in 
case of history of diabetes or renal insufficiency) at the study visit], type 2 diabetes 
mellitus (T2DM) [defined as history of diabetes or glycaemia >7.0 mmol/L], 
dyslipidemia (defined as history of hypercholesterolaemia or cholesterol-lowering 
therapy or an low-density lipoprotein (LDL) cholesterol above target according to the 
French recommendations [25], chronic renal failure (CRF) [defined as kidney damage 
or glomerular filtration rate (GFR) <60 mL/min/1.73 m2 for 3 months or more], and 
family history of myocardial infarction (MI). Furthermore, the Framingham Risk Score 
(FRS) [26], was used to estimate the 10-year risk for a CV event of an individual [range 
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from <5 % (low rLVNWRKLJKULVN@$OOWKHVHYDULDEOHVZHUHFROOHFWHGGXULQJD
one-to-one study visit for the parent study including the review of the medical charts. 
 
2.4. Statistical analysis 
All data presented in the Figure and Tables are expressed as mean and Standard 
Deviation (SD) for continuous variables, and as number and/or percentage of patients 
for categorical variables. Chi-square test (categorical variables) and Independent-
Samples t test (continuous variables) were used to evaluate the association between CV 
risk factors and SpA phenotype, and to compare the prevalence of SpA clinical 
characteristics and CV risk in Northern European vs. Mediterranean countries.  
A multiple logistic regression was performed to assess the variables potentially 
associated with high FRS )56 by including in the model the most important 
phenotypes and disease activity covariates. Those covariates which reflect CV risk were 
excluded from the model, with the aim to avoid the presence of similar components on 
both sides of the equation. Interactions, confounding factors and collinearity were 
tested, and all comparisons were bilateral considering pDVDVLJQLILFDQWUHVXOW 
SPSS 17.0 for Windows was used for the statistical analysis. 
 
2.5. Founding source 
The ASAS-COMOSPA parent study was conducted thanks to an unrestricted grant from 
Abbvie, Pfizer and UCB. This ancillary study has not any funding source. 
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3. Results 
Demographics and disease characteristics of the 2001 patients included are 
summarized in Table 1. Participants were predominantly males (1202, 60.1%), had an 
average age of 46.1 ± 13.3 years and a disease duration of 9.5 ± 10.4 years. A half of 
patients exhibited mixed involvement (50.1%), whereas 39.8% and 10.1% of patients 
presented only axial and only peripheral phenotype, respectively.  
In the entire population, the most prevalent CV risk factor was smoking (n=625, 
31.2%), followed by hypertension (n=488, 24.4%) and obesity (n=468, 23.4%). 
Prevalence of T2DM, dyslipidemia, family history of MI and CRF were 6.2%, 15.9%, 
18.0% and 2.2%, respectively. Regarding CVD, the estimated prevalence for IHD in our 
study was 3.2% whereas for stroke was 1.6% (Fig. 2). 
The analysis of the association between CV risk and SpA phenotype is shown in 
Table 2. Several CV risk factors were noted to be less frequent in axial SpA patients 
compared to patients with peripheral and/or mixed involvement. Particularly, axial SpA 
patients exhibited lower prevalence of hypertension (19.2% vs. 33.8% vs. 26.6%, for 
axial, peripheral and mixed phenotypes, respectively) (p<0.001) and T2DM (4.3% vs. 
8.5% vs. 7.4%, for axial, peripheral and mixed phenotypes, respectively) (p=0.010) than 
peripheral and mixed SpA patients. Obesity (19.0% vs. 24.9% vs. 26.8%, for axial, 
peripheral and mixed phenotypes, respectively) (p=0.001) and family history of MI 
(15.3% vs. 15.6% vs. 21.1%, for axial, peripheral and mixed phenotypes, respectively) 
(p=0.007) were less frequently detected in axial SpA compared to mixed SpA. 
Furthermore, dyslipidemia was less prevalent (13.9% vs. 28.4% vs. 15.2%, for axial, 
peripheral and mixed phenotypes, respectively), and FRS was lower (8.0 vs. 9.4 vs. 8.7, 
for axial, peripheral and mixed phenotypes, respectively) in axial and mixed SpA 
patients as compared to peripheral SpA (p<0.001). Regarding tobacco, a higher 
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prevalence of smoking was observed in axial SpA patients compared to peripheral and 
mixed SpA patients (38.1% vs. 27.4% vs. 26.5%, for axial, peripheral and mixed 
phenotypes, respectively) (p<0.001). Concerning CVD, there were no significant 
differences for stroke among SpA phenotypes; however, IHD was less frequent in axial 
and mixed SpA patients compared to peripheral SpA patients (2.4% vs. 7.0% vs. 3.2%, 
for axial, peripheral and mixed phenotypes, respectively) (p<0.05).  
SpA clinical characteristics and the prevalence of CV risk and CVD in patients from 
Northern European vs. Mediterranean countries was compared (Table 3). 
Geographically, 1353 patients (67.6%) belonged to Mediterranean area countries and 
648 (32.4%) to Northern European countries, with an average disease duration of 7.9 ± 
12.0 and 12.8 ± 12.3 years, respectively. A higher mean age (49.9±13.5 vs 44.28±12.7 
years, p<0.001) and longer disease duration (12.8±12.3 vs 7.9±12.0 years, p<0.001), 
was noted in north Europeans. These patients also have significantly higher frequency 
of HLA-B27 antigen (72.6% vs 56.6%, p<0.001), dactylitis (18.7% vs 13.2%, p<0.001), 
uveitis (26.4% vs 17.4%, p<0.001), psoriasis (35.8% vs 20.3%, p<0.001) and IBD 
(11.1% vs 7.0%, p=0.002). Regarding CV risk, higher prevalence of hypertension 
(34.7% vs 19.4%, p<0.001), dyslipidemia (19.3% vs 14.4%, p=0.005), obesity (29.3% 
vs 20.7%, p<0.001) and CRF (3.9% vs 1.5%, p=0.001) was observed in patients from 
countries of Northern European region vs. Mediterranean region. Further, a higher 
prevalence of IHD (6.2% vs 1.8%, p<0.001), was detected in patients from Northern 
European vs. Mediterranean countries. Detailed prevalence for CVD and CV risk 
factors per sex, age interval and country are summarised in an additional file [Appendix 
A, Tables S1-S10; See the supplementary material associated with this article online]. 
Finally, a multiple logistic regression model was used to identify potential predictors 
of high FRS (Table 4). A higher FRS was present in SpA patients from Northern 
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European vs. Mediterranean region (OR 1.69; p<0.001). Furthermore, elevated FRS was 
observed in patients with a longer disease duration (OR 1.09; p<0.001), peripheral 
involvement (OR 1.62; p=0.025), psoriasis (OR 1.83; p<0.001), presence of tender 
joints (OR 1.03; p=0.004) and elevated ESR levels (OR 1.01; p=0.040).  
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4. Discussion 
To our knowledge, this is the first study that has assessed the prevalence of CVD and 
its classical risk factors in patients with different SpA phenotypes together with the 
influence of the geographical area (Northern Europe vs. Mediterranean) in the 
prevalence of CV risk and SpA clinical characteristics. 
Several studies have suggested an increased risk of hypertension, T2DM, obesity and 
dyslipemia in the two most common subtypes of SpA, PsA [11,13,27] and AS 
[10,11,28], compared to the general population. However, studies evaluating the CV 
risk profile between both diseases have provided contradictory results [11,14,29], 
showing a similar or lower prevalence of CV risk in AS than PsA patients. The observed 
discrepancies may be due to the fact that these studies do not compared all clinical 
phenotypes present in SpA. The present analysis, conducted in the ASAS-COMOSPA 
database, is the first one that took into account the phenotypes of the disease. Our 
results demonstrated that axial SpA patients exhibited a lower prevalence of traditional 
CV risk factors than patients with peripheral and/or mixed phenotypes, and this could be 
associated to a lower development of CV events. Consistent with our results, previous 
data showed that predominantly axial SpA is related with a lower frequency of 
hypertension, dyslipidemia, T2DM and obesity [14,30] than PsA (a mainly peripheral 
disease). However, an increased prevalence of family history of MI was observed in 
patients with axial SpA, an independent risk factor that may contribute to a higher 
prevalence of CVD [30]. Finally, a higher prevalence of smoking was observed in 
patients with axial phenotype than in those with peripheral and mixed phenotype, as 
previously reported in AS patients [14,29].  
Regarding CV comorbidities, previous studies have demonstrated an increased risk 
of CV mortality in AS and PsA patients [31], with a prevalence of CV events similar for 
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both diseases [11,29]. However, as mentioned above, these studies did not consider the 
clinical phenotype of the disease. Our present study is the first one, to our knowledge, 
which showed that IHD has a lower prevalence in axial SpA patients than those with 
peripheral phenotype. Moreover, the decreased prevalence of CVD in axial SpA is 
consistent with our results demonstrating that these patients exhibit less classical CV 
risk factors (i.e. hypertension, obesity, T2DM, dyslipidemia and family history of MI) 
than peripheral and/or mixed SpA patients.  
The reason for the reduced prevalence of CVD and its traditional risk factors in axial 
SpA patients could be due to the low disease activity in these patients, which results in a 
decrease of pro-inflammatory state and, consequently, in a reduction in classical CV 
risk factors (i.e. dyslipidemia, T2DM, obesity). Nevertheless, in our present study, there 
are non-significant differences in disease activity between axial and peripheral 
phenotypes; although, mixed SpA patients exhibited higher levels of disease activity 
markers than axial and peripheral SpA patients. An additional file shows this in more 
detail (Appendix A, Table S11). Our findings are indicative of an inflammatory status at 
the recruitment moment and only a history of low activity during disease progression 
might explain the reduced CV events observed in axial SpA patients. Additional factors 
should be taken into account for the difference in CV risk between phenotypes. Perhaps 
one of the causes of the increased prevalence of vascular risk in peripheral SpA patient 
is the physical inactivity as a result of progressive joint damage. On the same note, PsA 
patients showed low levels of physical exercise [32] and in rheumatoid arthritis (a 
predominantly peripheral form) an association of physical inactivity with increased CV 
risk [33] has been demonstrated. Likewise, a higher prevalence of metabolic syndrome, 
an independent predictor of CV events, has been noted in patients with PsA, but not AS, 
compared to the general population [14].  
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 The comparison of the two population groups suggested that SpA patients from the 
two geographical regions displayed differences in phenotype, CV comorbidities and in 
classical CV risk factors. Specifically, SpA patients from Northern European countries 
showed a lower prevalence of axial involvement, as well as a higher mean age, longer 
disease duration, an elevated prevalence of HLA-B27 antigen and extra-articular 
manifestations than countries from Mediterranean region. In relation to CV risk, SpA 
patients from Northern European area showed a higher prevalence of traditional CV risk 
factors (i.e. obesity, hypertension, dyslipidemia, and CRF) and CV comorbidities (i.e. 
IHD) than those from Mediterranean countries. The increased CV events in Northern 
European region could be explained by the older age of the patients and longer mean 
disease duration, both factors related to the development of CVD [34,35]. Likewise, an 
HLA-B27-associated cardiac syndrome consisting of aortic insufficiency and atrial 
ventricular block has been described [36], demonstrating the implication of this antigen 
in CV pathogenesis. Nevertheless, the higher prevalence of peripheral involvement 
observed in this geographical area might also contribute to increased development of 
CV risk factors observed in these patients (Appendix A, Table S12). 
The prevalence of CV risk profile was different than what has been reported in 
healthy individuals from each geographical area. Specifically, in Northern Europe the 
prevalence of obesity was estimated at 11.8% in healthy individual (reference data from 
Netherlands) [37,38] whereas in our SpA patients it was 29.30%. However, global 
prevalence of dyslipidemia, hypertension and T2DM was similar in healthy individuals 
(23.2%, 31.4% and 7.9% respectively) and SpA patients (19.3%, 34.7% and 6.0% 
respectively). Regarding countries from Mediterranean region, we noted that the 
estimated prevalence of hypertension, dyslipidemia and T2DM was 42.6 %, 49.5 % and 
13.6 % in healthy individual (reference data from Spain) [39,40] and 19.4 %, 14.4 % 
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and 6.4 % in our SpA patients. In relation to obesity, we observed that the global 
prevalence was estimated at 29.7 % in healthy individuals and 20.7 % in SpA patients. 
Thus, our data suggest that disease phenotype may be involved in the development of 
CV comorbidities in SpA patients.  
This study presents some limitations. First, the study was performed in 2001 of the 
3984 patients who form the COMOSPA database, which can hamper the external 
validity of the study. Secondly, the prevalence of CVD might have been underestimated 
as a result of the inability of patients to participate or even died at a premature age, 
preventing them to collaborate in the study. Finally, the prevalence of CV comorbidities 
in these patients was variable across countries. This finding can be explained by the 
socioeconomic differences, which has an effect on health systems, and differences in 
diet, genetic and environment; however, it is possible that this may be also influenced 
by the selection type used in each country.  
Overall, our results seem to indicate that SpA phenotype and socio-demographic 
characteristics are associated with the CV risk observed in the two geographical areas. 
A better knowledge of the association between SpA and CV comorbidities is useful for 
the development of a comprehensive and integrated intervention in the prevention of 
CVD, for minimizing the impact of the CV risk, and for improving patients´ long-term 
outcome. 
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Figure legend section 
 
Figure 1. Distribution of the 2001 patients selected from the parent COMOSPA study.  
Figure 2. Prevalence of Cardiovascular risk factors and Cardiovascular Disease in the 
entire population.  
T2DM: type 2 diabetes mellitus. CRF: Chronic renal failure. MI: myocardial infarction 
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All results are presented as mean and Standard Deviation (SD), and as percentages for continuous and 
categorical variables, respectively.  
Percentages indicate number of patients with the covariate from the total number of patients in each 
category.  
HLA: Human leukocyte antigen; IBD: Inflammatory Bowel Disease. 
1HLA-B27: percentage from the total of available data (n=1543).  
 
Table 1. Demographic data and disease characteristics of the 2001 patients from the ASAS-COMOSPA 
study. 
 Global 
results 
 
(%) 
Axial 
involvement 
 
(%) 
Axial and 
peripheral 
involvement 
(%) 
Peripheral 
involvement 
 
(%) 
Number of patients 2001 797 (39.8) 1003 (50.1) 201 (10.1) 
Age (years), Mean (SD) 46.1 (13.3) 43.9 (12.6) 46.5 (13.3) 53.1(13.1) 
Gender (males)  1202 (60.1) 536 (67.3) 543 (54.1) 123 (61.2) 
Disease duration (years), Mean (SD)  9.5 (10.4) 9.2 (10.5) 10.0 (10.7) 8.3 (8.1) 
HLA-B271  967 (62.67) 471 (59.2) 454 (45.7) 42 (21.0) 
Enthesitis  805 (40.2) 208 (26.1) 526 (52.4) 71 (35.3) 
Dactylitis  299 (14.9) 0 (0) 212 (21.1) 87 (43.3) 
Uveitis  406 (20.3) 164 (20.6) 224 (22.3) 18 (9.0) 
Psoriasis 506 (25.3) 81 (10.2) 285 (28.4) 140 (69.7) 
IBD  167 (8.3) 56 (7.0) 106 (10.6) 5 (2.5) 
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All results are presented as percentages for categorical variables, and as mean and Standard Deviation (SD) 
for continuous variables. Percentages indicate number of patients with the covariate from the total number of 
patients in each disease clinical form.  
1
 Calculated using ANOVA for the covariate FRS with Post-hoc analysis using Sidak test, and a chi-square 
test for the rest of covariates.  
a
 VLJQLILFDQWGLIIHUHQFHVSUHJDUGLQJ$[LDOLQYROYHPHQW 
b VLJQLILFDQWGLIIHUHQFHVSUHJDUGLQJ$[LDO and Peripheral involvement. 
Table 2. Comparison of the prevalence for CVD and CV risk factors among disease clinical forms.  
 
Axial 
involvement 
 
n=797 
(%) 
Axial and 
peripheral 
involvement 
n=1003 
(%) 
Peripheral 
involvement 
 
n=201 
(%) 
 
 
p-value1 
Hypertension 153 (19.2) 267 (26.6)a 68 (33.8)a <0.001 
T2DM 34 (4.3) 74 (7.4)a 17 (8.5)a 0.010 
Dislypidemia 111 (13.9) 152 (15.2) 57 (28.4)a,b <0.001 
Obesity 151 (19.0) 267 (26.8)a 50 (24.9) 0.001 
CRF 15 (1.9) 25 (2.5) 5 (2.5) n.s. 
Tobacco 304 (38.1) 266 (26.5)a 55 (27.4)a <0.001 
Family history MI 122 (15.3) 206 (21.1)a 31 (15.6) 0.007 
IHD 19 (2.4) 32 (3.2) 14 (7.0)a,b 0.005 
Stroke 12 (1.5) 16 (1.6) 5 (2.5) n.s. 
FRS, Mean (SD) 8.0 (8.1) 8.7 (8.7) 12.2 (9.4)a,b <0.001 
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CRF: Chronic Renal Failure; IHD: Ischemic heart disease; FRS: Framingham Risk Score. MI: Miocardial 
infarction. T2DM: Type 2 diabetes mellitus.  
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Table 3. Comparison of the prevalence of disease characteristics, CV risk factors and CVD in Northern European 
countries vs. Mediterranean countries. 
 Global results  
 
 
n=2001 
(%) 
Mediterranean 
countries 
 
n=1353 
(%) 
Northern 
European 
countries 
n=648 
(%) 
  
 
OR (95% CI) 
 
p-value1 
Age (years), Mean (SD) 46.1 (13.3) 44.28 (12.7) 49.95 (13.5) 
 
1.03 (1.02-1.04) <0.001 
Sex (male)  1202 (60.1) 804 (59.4) 398 (61.4)  1.09 (0.90-1.32) n.s. 
Disease d (years),Mean (SD) 9.5 (10.4) 7.9 (12.0) 12.8 (12.3) 
 
1.04 (1.03-1.05) <0.001 
HLA- B272 967 (62.67) 604 (56.6) 363 (76.2) 
 
2.46 (1.93-3.14) <0.001 
Clinical form    
 
 
 
  - Axial (ref.)  797 (39.8) 585 (43.2) 212 (32.7) 
 
Reference 
 
  - Axial and peripheral 1003 (50.1) 671 (49.6) 332 (51.2) 
 
1.36 (1.11-1.67) 0.003 
  - Peripheral 201 (10.1) 97 (7.17) 104 (16.05) 
 
2.96 (2.15-4.07) <0.001 
Enthesitis  805 (14.9) 547 (40.4) 258 (39.8)  0.97 (0.80-1.18) n.s. 
Dactylitis  299 (40.2) 178 (13.2) 121 (18.7) 
 
1.52 (1.18-1.95) 0.001 
Uveitis  406 (20.3) 235 (17.4) 171 (26.4) 
 
1.71 (1.37-2.14) <0.001 
Psoriasis  506 (23.3) 274 (20.3) 232 (35.8) 
 
2.19 (1.78-2.70) <0.001 
IBD  167 (8.3) 95 (7.0) 72 (11.1) 
 
1.65 (1.2-2.28) 0.002 
Hypertension  488 (24.4) 263 (19.4) 255 (34.7) 
 
2.20 (1.78-2.72) <0.001 
T2DM  125 (6.2) 86 (6.4) 39 (6.0)  0.94 (0.64-1.39) n.s. 
Dyslipidemia  320 (15.9) 195 (14.4) 125 (19.3) 
 
1.42 (1.11-1.81) 0.005 
Obesity  468 (23.4) 280 (20.7) 188 (29.3) 
 
1.59 (1.28-1.96) <0.001 
CRF 45 (2.2) 20 (1.5) 25 (3.9) 
 
2.67 (1.47-4.85) 0.001 
Smoking status  625 (31.2) 406 (30.0) 219 (33.8)  1.19 (0.97-1.45) n.s. 
Family history of MI  359 (18.0) 232 (17.1) 127 (19.6)  1.16 (0.92-1.48) n.s. 
IHD  65 (3.2) 25 (1.8) 40 (6.2) 
 
3.49 (2.10-5.81) <0.001 
Stroke  33 (1.6) 17 (1.3) 16 (2.5)  1.99 (0.99-3.96) n.s. 
FRS,  Mean  (SD) 8.8 (8.6) 7.49 (7.8) 11.42 (9.6) 
 
1.05 (1.04-1.06) <0.001 
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All results are presented as mean and Standard Deviation (SD), and number of patients (%) for continuous and 
categorical variables, respectively. Percentages indicate number of patients with the covariate from the total number of 
patients in each category.  
1
 Calculated using a univariate logistic regression. Mediterranean countries were used as the reference category. The 
OR represents Northern European countries vs. Mediterranean countries.  
2
 Number of HLA-B27 positive patients from the total of available data (n=1532). 
Disease d: disease duration. HLA: Human leukocyte antigen; CI: Confidence interval; CRF: Chronic Renal Failure; 
FRS: Framingham Risk score; IBD: Inflammatory bowel disease; IHD: Ischemic heart disease; MI: Myocardial 
Infarction; OR: Odds Ratio; SD: Standard deviation; T2DM: Type 2 diabetes mellitus. Ref.: Reference.  
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Table 4. Identification of potential predictors of high Framingham index score1.  
 OR (95% CI) p-value 
North Europe (ref. Mediterranean patients) 1.68 (1.28 ± 2.21) <0.001 
Disease duration (years) 1.09 (1.08 ± 1.11) <0.001 
Clinical form: 
   -Mixed involvement (ref. axial) 
   -Peripheral involvement (ref. axial) 
 
1.02 (0.76 ± 1.37) 
1.85 (1.25 ± 2.75) 
 
0.877 
0.002 
Psoriasis 1.99 (1.47 ± 2.69) <0.001 
Dactylitis 0.65 (0.45 ± 0.95) 0.024 
Number of tender joints 1.03 (1.01 ± 1.05) 0.003 
ESR 1.01 (1.00 ± 1.01) 0.042 
 Hosmer-Lemeshow test: F2 square = 8.916, p=0.349 
1
 Calculated using a multiple logistic regression. Primary outcome: Framingham risk 
VFRUH 
Variables included in the model: Disease duration, geographical area, HLA-B27, 
clinical form, dactilitis, enthesitis, uveitis, psoriasis, inflammatory bowel disease, 
number of tender joints, number of swollen joints, BASDAI (Bath Ankylosing 
Spondylitis Disease Activity Index), ASDAS-CPR (Ankylosing Spondylitis Disease 
Activity Score-CRP), CPR (C Reactive Protein), ESR (Erythrocyte Sedimentation Rate) 
and PGVAS (Patient Global Visual Analogue Scale). 
Ref.: Reference.  
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Fig. 1. Distribution of the 2001 patients selected from the parent COMOSPA 
study.  
 
 
3984 patients from the 
parent study 
2020 patients from the 10 
selected countries 
19 patients excluded 
because of socio-
demographic missing data 
2001 patients included in 
the final analysis 
1353 patients from 
Mediterranenan countries 
648 patients from Northern 
Europe 
1964 patients from the 
excluded countries 
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 Fig. 2. Prevalence of Cardiovascular risk factors and Cardiovascular Disease in 
the entire population.  
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